LANXESS is pursuing additional cost reductions, portfolio adjustments, and debt-reduction measures as weak agriculture and construction markets continue to pressure earnings. Its FORWARD! program has delivered about €150 million in savings, with another €170 million expected through 2028, including restructuring and capacity shifts toward pharmaceuticals. Second-quarter EBITDA pre rose to €152 million from €94 million in the first quarter, while free cash flow turned positive, but management cautioned that the improvement may not represent a trend. The company maintained its 2026 EBITDA pre guidance of €450 million to €550 million and expects third-quarter EBITDA pre of €130 million to €150 million. Deleveraging remains a priority, with LANXESS targeting net debt below 2.5 times EBITDA and a return to sustainable investment-grade status, including monetizing its Envalior stake.
LANXESS AktiengesellschaftWeak agriculture and construction markets continue to pressure earnings, with management cautioning the Q2 improvement may not be a trend.
